Physiology and Pathophysiology of the Blood-Brain Barrier: P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central Nervous System Drug Delivery
Restricted accessMeeting reportFirst published online December, 2012
Physiology and Pathophysiology of the Blood-Brain Barrier: P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central Nervous System Drug Delivery
The blood-brain barrier (BBB) is a physical and metabolic barrier that separates the central nervous system from the peripheral circulation. Central nervous system drug delivery across the BBB is challenging, primarily because of the physical restriction of paracellular diffusion between the endothelial cells that comprise the microvessels of the BBB and the activity of efflux transporters that quickly expel back into the capillary lumen a wide variety of xenobiotics. Therapeutic manipulation of protein trafficking is emerging as a novel means of modulating protein function, and in this minireview, the targeting of the trafficking of 2 key BBB proteins, P-glycoprotein and occludin, is presented as a novel, reversible means of optimizing central nervous system drug delivery.
ZlokovicBV, ApuzzoML. Strategies to circumvent vascular barriers of the central nervous system. Neurosurgery. 1998; 43 (4): 877–878.
2.
ZlokovicBV. Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res. 1995; 12 (10): 1395–1406.
3.
HawkinsBT, DavisTP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005; 57 (2): 173–185.
4.
AbbottNJ, PatabendigeAA, DolmanDE, . Structure and function of the blood-brain barrier. Neurobiol Dis. 2010; 37 (1): 13–25.
5.
AbbottNJ, RonnbackL, HanssonE. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7 (1): 41–53.
6.
PardridgeWM. Drug targeting to the brain. Pharm Res. 2007; 24 (9): 1733–1744.
7.
el-BachaRS, MinnA.Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand). 1999; 45 (1): 15–23.
8.
RonaldsonPT, DavisTP. Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery. Ther Deliv. 2011; 2 (8): 1015–1041.
9.
PettyMA, LoEH. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol. 2002; 68 (5): 311–323.
RonaldsonPT, DavisTP. Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des. 2012; 18 (25): 3624–3644.
12.
VangilderRL, RosenCL, BarrTL, . Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ther. 2011; 130 (3): 239–247.
13.
BanksWA, EricksonMA. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis. 2010; 37 (1): 26–32.
14.
StanimirovicDB, FriedmanA. Pathophysiology of the neurovascular unit: disease cause or consequence?J Cereb Blood Flow Metab. 2012; 32 (7): 1207–1221.
15.
HomS, FleegalMA, EgletonRD. Comparative changes in the blood-brain barrier and cerebral infarction of SHR and WKY rats. Am J Physiol Regul Integr Comp Physiol. 2007; 292 (5): R1881–R1892.
StrazzaM, PirroneV, WigdahlB, . Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res. 2011; 1399: 96–115.
32.
BanksWA. The dam breaks: disruption of the blood-brain barrier in diabetes mellitus. Am J Physiol Heart Circ Physiol. 2006; 291 (6): H2595–H2596.
33.
WuKC, PanHJ, YinHS, . Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with type 2 diabetes. Life Sci. 2009; 85 (23-26): 775–781.
34.
HawkinsBT, LundeenTF, NorwoodKM, . Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007; 50 (1): 202–211.
35.
DeKlerk OL, BoskerFJ, LuurtsemaG, . The role of P-glycoprotein in psychiatric disorders: a reliable guard of the brain?Cent Nerv Syst Agents Med Chem. 2011; 11 (3): 197–209.
36.
ReniaL, WuHowland S, ClaserC. Cerebral malaria: mysteries at the blood-brain barrier. Virulence. 2012; 3 (2).
ChenY, HuangW. Non-impact, blast-induced mild TBI and PTSD: concepts and caveats. Brain Inj. 2011; 25 (7-8): 641–650.
39.
HelmyA, DeSimoni MG, GuilfoyleMR, . Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol. 2011; 95 (3): 352–372.
40.
PopV, BadautJ. A neurovascular perspective for long-term changes after brain trauma. Transl Stroke Res. 2011; 2 (4): 533–545.
41.
Frontczak-BaniewiczM, ChrapustaSJ, SulejczakD. Long-term consequences of surgical brain injury—characteristics of the neurovascular unit and formation and demise of the glial scar in a rat model. Folia Neuropathol. 2011; 49 (3): 204–218.
42.
BeggsS, LiuXJ, KwanC, . Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol Pain. 2010; 6: 74.
43.
NicoB, RibattiD. Morphofunctional aspects of the blood-brain barrier. Curr Drug Metab. 2012; 13 (1): 50–60.
44.
KesariS. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol. 2011; 38 (suppl 4): S2–S10.
45.
AgarwalS, HartzAM, ElmquistWF, . Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des. 2011; 17 (26): 2793–2802.
46.
AronicaE, SisodiyaSM, GorterJA. Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev. 2012; 64 (10): 919–929.
HartzAM, NotenboomS, BauerB. Signaling to P-glycoprotein—a new therapeutic target to treat drug-resistant epilepsy?Drug News Perspect. 2009; 22 (7): 393–397.
49.
LazarowskiA, CzornyjL, LubieniekiF, . ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia. 2007; 48 (suppl 5): 140–149.
50.
WolkaAM, HuberJD, DavisTP. Pain and the blood-brain barrier: obstacles to drug delivery. Adv Drug Deliv Rev. 2003; 55 (8): 987–1006.
51.
NeuweltEA, BauerB, FahlkeC, . Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci. 2011; 12 (3): 169–182.
52.
MaeM, ArmulikA, BetsholtzC. Getting to know the cast-cellular interactions and signaling at the neurovascular unit. Curr Pharm Des. 2011; 17 (26): 2750–2754.
53.
HungMC, LinkW. Protein localization in disease and therapy. J Cell Sci. 2011; 124 (pt 20): 3381–3392.
54.
MillerDS, BauerB, HartzAM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008; 60 (2): 196–209.
55.
MillerDS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci. 2010; 31 (6): 246–254.
RobertsLM, BlackDS, RamanC, . Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience. 2008; 155 (2): 423–438.
58.
BendayanR, RonaldsonPT, GingrasD, . In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem. 2006; 54 (10): 1159–1167.
59.
VirgintinoD, RobertsonD, ErredeM, . Expression of P-glycoprotein in human cerebral cortex microvessels. J Histochem Cytochem. 2002; 50 (12): 1671–1676.
60.
SunJ, HeZG, ChengG, . Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit. 2004; 10 (1): RA5-RA14.
61.
UenoM, NakagawaT, WuB, . Transporters in the brain endothelial barrier. Curr Med Chem. 2010; 17 (12): 1125–1138.
62.
PotschkaH. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther. 2010; 125 (1): 118–127.
63.
HartzAM, BauerB. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv. 2010; 10 (5): 293–304.
64.
HodgesLM, MarkovaSM, ChinnLW, . Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011; 21 (3): 152–161.
65.
PalmeiraA, SousaE, VasconcelosMH. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012; 19 (13): 1946–2025.
66.
KayeSB. Reversal of drug resistance in ovarian cancer: where do we go from here?J Clin Oncol. 2008; 26 (16): 2616–2618.
67.
SzakacsG, PatersonJK, LudwigJA, . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5 (3): 219–234.
68.
FletcherJI, HaberM, HendersonMJ, . ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010; 10 (2): 147–156.
69.
KannanP, JohnC, ZoghbiSS, . Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009; 86 (4): 368–377.
70.
ChooEF, KurnikD, MuszkatM, . Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. J Pharmacol Exp Ther. 2006; 317 (3): 1012–1018.
71.
BauerB, HartzAM, FrickerG, . Modulation of P-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood). 2005; 230 (2): 118–127.
72.
HawkinsBT, RigorRR, MillerDS. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ proteolysis protection assay. J Cereb Blood Flow Metab. 2010; 30 (9): 1593–1597.
73.
MahringerA, OttM, ReimoldI, . The ABC of the blood-brain barrier—regulation of drug efflux pumps. Curr Pharm Des. 2011; 17 (26): 2762–2770.
74.
SeelbachMJ, BrooksTA, EgletonRD, . Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein. J Neurochem. 2007; 102 (5): 1677–1690.
75.
FujitaI, OkumuraT, SakakibaraA, . Involvement of inflammation in severe post-operative pain demonstrated by pre-surgical and post-surgical treatment with piroxicam and ketorolac. J Pharm Pharmacol. 2012; 64 (5): 747–755.
76.
CostantiniR, AffaitatiG, FabrizioA, . Controlling pain in the post-operative setting. Int J Clin Pharmacol Ther. 2011; 49 (2): 116–127.
Cordon-CardoC, O'BrienJP, CasalsD, . Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989; 86 (2): 695–698.
79.
WangJS, TaylorR, RuanY, . Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology. 2004; 29 (3): 551–557.
80.
SchinkelAH, SmitJJ, vanTellingen O, . Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994; 77 (4): 491–502.
81.
FuD, AriasIM. Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol. 2012; 44 (3): 461–464.
82.
PorcelliL, LemosC, PetersGJ, . Intracellular trafficking of MDR transporters and relevance of SNPs. Curr Top Med Chem. 2009; 9 (2): 197–208.
83.
JodoinJ, DemeuleM, FenartL, . P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem. 2003; 87 (4): 1010–1023.
84.
LajoieP, GoetzJG, DennisJW, . Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol. 2009; 185 (3): 381–385.
85.
DemeuleM, JodoinJ, GingrasD, . P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett. 2000; 466 (2-3): 219–224.
86.
GuoZ, ZhuJ, ZhaoL, . Expression and clinical significance of multidrug resistance proteins in brain tumors. J Exp Clin Cancer Res. 2010; 29: 122.
87.
BarakatS, TurcotteS, DemeuleM, . Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. Biochem Biophys Res Commun. 2008; 372 (3): 440–446.
88.
BarakatS, DemeuleM, PilorgetA, . Modulation of P-glycoprotein function by caveolin-1 phosphorylation. J Neurochem. 2007; 101 (1): 1–8.
89.
McCaffreyG, StaatzWD, Sanchez-CovarrubiasL, . P-glycoprotein trafficking at the blood-brain barrier altered by peripheral inflammatory hyperalgesia. J Neurochem. 2012; 122 (5): 962–975.
90.
FeldmanGJ, MullinJM, RyanMP. Occludin: structure, function and regulation. Adv Drug Deliv Rev. 2005; 57 (6): 883–917.
91.
DobrogowskaDH, VorbrodtAW. Immunogold localization of tight junctional proteins in normal and osmotically-affected rat blood-brain barrier. J Mol Histol. 2004; 35 (5): 529–539.
92.
BrooksTA, HawkinsBT, HuberJD, . Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol. 2005; 289 (2): H738–H743.
93.
HuberJD, HauVS, BorgL, . Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol. 2002; 283 (4): H1531–H1537.
94.
HuberJD, WittKA, HomS, . Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol. 2001; 280 (3): H1241–H1248.
95.
LochheadJJ, McCaffreyG, Sanchez-CovarrubiasL, . Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain. Am J Physiol Heart Circ Physiol. 2012; 302 (3): H582–H593.
96.
McCaffreyG, SeelbachMJ, StaatzWD, . Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem. 2008; 106 (6): 2395–2409.
97.
HauVS, HuberJD, CamposCR, . Effect of lambda-carrageenan-induced inflammatory pain on brain uptake of codeine and antinociception. Brain Res. 2004; 1018 (2): 257–264.
98.
XieR, Hammarlund-UdenaesM.Blood-brain barrier equilibration of codeine in rats studied with microdialysis. Pharm Res. 1998; 15 (4): 570–575.
99.
BradburyMW, PatlakCS, OldendorfWH. Analysis of brain uptake and loss or radiotracers after intracarotid injection. Am J Physiol. 1975; 229 (4): 1110–1115.
100.
GordhT, SharmaHS. Chronic spinal nerve ligation induces microvascular permeability disturbances, astrocytic reaction, and structural changes in the rat spinal cord. Acta Neurochir Suppl. 2006; 96: 335–340.
101.
CumminsPM. Occludin: one protein, many forms. Mol Cell Biol. 2012; 32 (2): 242–250.
102.
HarhajNS, AntonettiDA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol. 2004; 36 (7): 1206–1237.
103.
BlasigIE, BellmannC, CordingJ, . Occludin protein family: oxidative stress and reducing conditions. Antioxid Redox Signal. 2011; 15 (5): 1195–1219.
104.
TsukitaS, FuruseM, ItohM. Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol. 1999; 11 (5): 628–633.
BlasigIE, WinklerL, LassowskiB, . On the self-association potential of transmembrane tight junction proteins. Cell Mol Life Sci. 2006; 63 (4): 505–514.
107.
WalterJK, CastroV, VossM, . Redox-sensitivity of the dimerization of occludin. Cell Mol Life Sci. 2009; 66 (22): 3655–3662.
108.
WalterJK, RueckertC, VossM, . The oligomerization of the coiled coil-domain of occludin is redox sensitive. Ann N Y Acad Sci. 2009; 1165: 19–27.
109.
YaffeY, ShepshelovitchJ, NevoI, . The MARVEL transmembrane motif of occludin mediates oligomerization and targeting to the basolateral surface in epithelia. J Cell Sci. 2012; 125 (Pt 15): 3545–3556.
110.
RaleighDR, MarchiandoAM, ZhangY, . Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions. Mol Biol Cell. 2010; 21 (7): 1200–1213.
111.
FuruseM, ItohM, HiraseT, . Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol. 1994; 127 (6 pt 1): 1617–1626.
112.
FanningAS, LittleBP, RahnerC, . The unique-5 and -6 motifs of ZO-1 regulate tight junction strand localization and scaffolding properties. Mol Biol Cell. 2007; 18 (3): 721–731.
113.
DorfelMJ, HuberO. Modulation of tight junction structure and function by kinases and phosphatases targeting occludin. J Biomed Biotechnol. 2012; 2012: 807356.
114.
Barrios-RodilesM, BrownKR, OzdamarB, . High-throughput mapping of a dynamic signaling network in mammalian cells. Science. 2005; 307 (5715): 1621–1625.
115.
OzdamarB, BoseR, Barrios-RodilesM, . Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005; 307 (5715): 1603–1609.
MorimotoS, NishimuraN, TeraiT, . Rab13 mediates the continuous endocytic recycling of occludin to the cell surface. J Biol Chem. 2005; 280 (3): 2220–2228.
118.
TrawegerA, FangD, LiuYC, . The tight junction-specific protein occludin is a functional target of the E3 ubiquitin-protein ligase itch. J Biol Chem. 2002; 277 (12): 10201–10208.
MiticLL, Van ItallieCM, Anderson JM. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol. 2000; 279 (2): G250–G254.
121.
FujimotoK. Freeze-fracture replica electron microscopy combined with SDS digestion for cytochemical labeling of integral membrane proteins. Application to the immunogold labeling of intercellular junctional complexes. J Cell Sci. 1995; 108 (pt 11): 3443–3449.
MacdonaldJL, PikeLJ. A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res. 2005; 46 (5): 1061–1067.
124.
McCaffreyG, StaatzWD, QuigleyCA, . Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J Neurochem. 2007; 103 (6): 2540–2555.
125.
HuaVB, ChangAB, TchieuJH, . Sequence and phylogenetic analyses of 4 TMS junctional proteins of animals: connexins, innexins, claudins and occludins. J Membr Biol. 2003; 194 (1): 59–76.
126.
McCaffreyG, WillisCL, StaatzWD, . Occludin oligomeric assemblies at tight junctions of the blood-brain barrier are altered by hypoxia and reoxygenation stress. J Neurochem. 2009; 110 (1): 58–71.
127.
LochheadJJ, McCaffreyG, QuigleyCE, . Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J Cereb Blood Flow Metab. 2010; 30 (9): 1625–1636.
128.
DavisJR, KakarM, LimCS. Controlling protein compartmentalization to overcome disease. Pharm Res. 2007; 24 (1): 17–27.
129.
GonnordP, BlouinCM, LamazeC.Membrane trafficking and signaling: two sides of the same coin. Semin Cell Dev Biol. 2012; 23 (2): 154–164.
130.
De MatteisMA, LuiniA. Mendelian disorders of membrane trafficking. N Engl J Med. 2011; 365 (10): 927–938.
131.
KondapakaSB, SinghSS, DasmahapatraGP, . Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003; 2 (11): 1093–1103.
132.
RichardsonPG, EngC, KolesarJ, . Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012; 8 (5): 623–633.
133.
SunW, ModakS. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther. 2012; 5: 21–29.
134.
WhistlerJL. Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012.
135.
GeorgoussiZ, GeorgantaEM, MilliganG. The other side of opioid receptor signalling: regulation by protein-protein interaction. Curr Drug Targets. 2012; 13 (1): 80–102.
136.
ArttamangkulS, LauEK, LuHW, . Desensitization and trafficking of mu-opioid receptors in locus ceruleus neurons: modulation by kinases. Mol Pharmacol. 2012; 81 (3): 348–355.
137.
van RijnRM, WhistlerJL, WaldhoerM. Opioid-receptor-heteromer-specific trafficking and pharmacology. Curr Opin Pharmacol. 2010; 10 (1): 73–79.
138.
HenleyJM, BarkerEA, GlebovOO. Routes, destinations and delays: recent advances in AMPA receptor trafficking. Trends Neurosci. 2011; 34 (5): 258–268.
MaoLM, GuoML, JinDZ, . Post-translational modification biology of glutamate receptors and drug addiction. Front Neuroanat. 2011; 5: 19.
141.
MukherjeeS, TessemaM, Wandinger-NessA.Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res. 2006; 98 (6): 743–756.
142.
SmithTH, Sim-SelleyLJ, SelleyDE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?Br J Pharmacol. 2010; 160 (3): 454–466.
143.
BunnettNW, CottrellGS. Trafficking and signaling of G protein-coupled receptors in the nervous system: implications for disease and therapy. CNS Neurol Disord Drug Targets. 2010; 9 (5): 539–556.
144.
XuZQ, ZhangX, ScottL. Regulation of G protein-coupled receptor trafficking. Acta Physiol (Oxf). 2007; 190 (1): 39–45.
LiseS, BuchanD, PontilM, . Predictions of hot spot residues at protein-protein interfaces using support vector machines. PLoS One. 2011; 6 (2): e16774.
147.
FinkA, Sal-ManN, GerberD. Transmembrane domains interactions within the membrane milieu: principles, advances and challenges. Biochim Biophys Acta. 2012; 1818 (4): 974–983.
148.
VazquezA. Protein interaction networks. In:AlzateO (Ed.) Neuroproteomics. Boca Raton (FL): CRC Press; 2010. Chapter 8. Available from: http://www.ncbi.nlm.nih.gov/books/NBK56024/. Accessed October 17, 2012
149.
DavisFP, SaliA. The overlap of small molecule and protein binding sites within families of protein structures. PLoS Comput Biol. 2010; 6 (2): e1000668.
150.
RajasekaranS. Computational techniques for motif search. Front Biosci. 2009; 14: 5052–5065.
151.
ZeytuniN, ZarivachR. Structural and functional discussion of the tetra-trico-peptide repeat, a protein interaction module. Structure. 2012; 20 (3): 397–405.
ArkinMR, WhittyA. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr Opin Chem Biol. 2009; 13 (3): 284–290.
155.
StraussHM, KellerS. Pharmacological interference with protein-protein interactions mediated by coiled-coil motifs. Handb Exp Pharmacol. 2008; (186): 461–482.
156.
DietzGP, BahrM. Synthesis of cell-penetrating peptides and their application in neurobiology. Methods Mol Biol. 2007; 399: 181–198.
157.
BolhassaniA. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta. 2011; 1816 (2): 232–246.
158.
ZhaoTX, MartinkoAJ, LeVH. Development of agents that modulate protein-protein interactions in membranes. Curr Pharm Des. 2010; 16 (9): 1055–1062.
159.
JubbH, HiguerueloAP, WinterA, . Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol Sci. 2012; 33 (5): 241–248.
160.
vonKleist L, HauckeV. At the crossroads of chemistry and cell biology: inhibiting membrane traffic by small molecules. Traffic. 2012; 13 (4): 495–504.
161.
MasonJM. Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med Chem. 2010; 2 (12): 1813–1822.
162.
RajadhyakshaM, BoydenT, LirasJ, . Current advances in delivery of biotherapeutics across the blood-brain barrier. Curr Drug Discov Technol. 2011; 8 (2): 87–101.
163.
BellavanceMA, BlanchetteM, FortinD. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J. 2008; 10 (1): 166–177.
164.
BegleyDJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004; 104 (1): 29–45.
165.
KrolS. Challenges in drug delivery to the brain: nature is against us. J Control Release. 2012May17[E-pub ahead of print].
166.
OrthmannA, FichtnerI, ZeisigR. Improving the transport of chemotherapeutic drugs across the blood-brain barrier. Expert Rev Clin Pharmacol. 2011; 4 (4): 477–490.
167.
ChenY, LiuL. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012; 64 (7): 640–665.
168.
PardridgeWM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012August29[E-pub ahead of print].
169.
BattagliaL, GallarateM. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012; 9 (5): 497–508.
170.
RollerovaE, ScsukovaS, JurcovicovaJ, . Polymeric nanoparticlesVtargeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities. Endocr Regul. 2011; 45 (1): 49–60.
171.
CraparoEF, BondiML, PitarresiG, . Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther. 2011; 17 (6): 670–677.
